Combined growth factors enhanced angiogenic potential of #cordblood derived mononuclear cells transplanted to ischemic limbs.

http://www.ncbi.nlm.nih.gov/pubmed/21782826

Potential novel therapy for the treatment of ischemic cardiovascular disease due to the cultured cord blood MNCs have increased level of engraftment and angiogenic potential.

---------------------

J Mol Cell Cardiol. 2011 Nov;51(5):702-12. Epub 2011 Jul 19.

Combined growth factors enhanced angiogenic potential of cord blood-derived mononuclear cells transplanted to ischemic limbs.

Kim MH, Zhang HZ, Kim SW.

Source

Department of Cardiology, College of Medicine, Dong-A University, Regional Clinical Center, Dong-A University Hospital, Busan, South Korea.

Abstract

Stem cell therapy has recently been limited by poor engraftment and the marginal influence of the administered cells. This study aimed to enhance the survival and angiogenic capacity of human umbilical cord blood (UCB)-derived mononuclear cells (MNCs) and to demonstrate their therapeutic effects on experimental ischemia. A specific culture medium containing five growth factors (Flt-3L, EGF, TPO, FGF and IGF-1) augmented cell proliferation, adhesion potential as well as stimulated MNCs to become progenitor-like cells. In addition, qRT-PCR demonstrated that MNCs cultured with these five growth factors (5f-MNCs) markedly up-regulated multiple angiogenic, arteriogenic and anti-apoptotic factors compared with uncultured MNCs. In an ischemic hindlimb model, the injection of 5f-MNCs prevented limb loss and augmented blood perfusion, capillary density, vascular maturation and angiogenic cytokines in the affected tissues. In addition, the 5f-MNCs exhibited an increased engraftment rate and an endothelial phenotype and stimulated angiogenic factors in ischemic hindlimbs as demonstrated by flow cytometric, immunohistochemical and qRT-PCR analyses. Taken together, these data suggest that 5f-MNCs could be used as a novel therapy for the treatment of ischemic cardiovascular disease due to their increased level of engraftment and angiogenic potential.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PMID:

 

21782826

 

[PubMed - indexed for MEDLINE]